Advanced Search:
Equity Index Forex Crypto Commodity

MDXG - MiMedx Group

$6.30  0.03 (0.56%)

Updated: 11:13 Apr 29, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

MiMedx Group's Position Within the Medical Devices Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

MIMEDX GROUP - HISTORICAL DATA 6M

  • Last price

    $ 6.30

  • Daily change

    $ 0.03

  • Previous Close

    $ 6.27

  • Last Updated

    11:13 Apr 29, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.89 -0.47 0.08 0.02

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 2.19 1.95 2.06 2.11

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A N/A 24.44% 4.45%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 6.36 -7.69% 6.89 -9.34% 7.6

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.79 45.36 0.56 44.13

MiMedx Group Technical Analysis News

MiMedx Group

1775 West Oak Commons Court, NE
Marietta, GA 30062
United States
770 651 9100
http://www.mimedx.com

Sectors: Healthcare
Industry: Medical Devices
F. Time Employees: 735
Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Corporate Governance

MiMedx Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

MIMEDX GROUP'S HOLDERS RANK

List of holders with stock participation in MiMedx Group.

Holder Rank Holder Shares Date Reported % Out Value